Research published in JAMA linking testosterone therapy to higher heart risks was covered on one of last night’s national news broadcasts, as well as on several major websites, although it received little coverage in major print media.
The CBS Evening News reported that new research suggests that testosterone replacement therapy may be linked to heart risks in certain individuals.
The Wall Street Journal (11/6, Beck, Subscription Publication, 5.91M) reports that for the study, investigators looked at data on more than 8,700 men with low testosterone who underwent coronary angiography at some time between 2005 and 2011 in the US Veterans Affairs health system.
The Los Angeles Times (11/6, Healy, 3.07M) “Science Now” blog reports that patients “taking testosterone were 30% more likely to suffer an adverse event – a stroke, a heart attack or death.”
Forbes (11/6, 6.03M) contributor Larry Husten writes that “after adjusting for differences between the groups there was a significant 29% increase in risk associated with testosterone (CI 1.05-1.58, p = 0.02).” The researchers found that “the effect size was the same in the groups of people who had coronary artery disease and those who did not.”
AFP (11/6) reports that “the increased risk of catastrophic events was especially notable, said researcher Anne Cappola of the University of Pennsylvania, because ‘the men who were taking testosterone in this study were slightly healthier to begin with.’”
The CNN (11/6, 14.53M) “The Chart” blog reports, however, that some physicians “who looked at the study questioned the methods, saying many of these men already had heart issues.”
Bloomberg News (11/6, Ostrow, 1.91M) points out that previous research on “testosterone supplements...in elderly males, funded by the U.S. National Institute on Aging and run at Boston Medical Center, was” halted after “an audit found it caused more heart attacks and high blood pressure.” Also covering the story are Reuters (11/6, Pittman), the AP (11/6, Tanner), the NBC News (11/6, Alexander, 6.79M) website, HealthDay (11/6, Dotinga, 5K),MedPage Today (11/6, Raeburn, 122K), and Medscape (11/6, O'Riordan, 164K).
No comments:
Post a Comment